ATX-MS-1467 for RRMS
A New Peptide Vaccine for Multiple Sclerosis Succeeds in Phase IIa
ATX-MS-1467 | MS Society
After Merck KGaA rejection, Apitope advances MS drug on strength of phase 2a safety, lesion reduction data | Fierce Biotech
A New Peptide Vaccine for Multiple Sclerosis Succeeds in Phase IIa
ATX-MS-1467 Induces Long-Term Tolerance to Myelin Basic Protein in (DR2 × Ob1)F1 Mice by Induction of IL-10-Secreting iTregs | SpringerLink
Apitope Announces Enrolment Completion in Phase IIA Clinical Trial of ATX-MS -1467 | Technology Networks
Brain Sciences | Free Full-Text | Recent Advances in Antigen-Specific Immunotherapies for the Treatment of Multiple Sclerosis
Enrolment completes for Phase IIa trial of ATX-MS-1467
ATX-MS-1467 Induces Long-Term Tolerance to Myelin Basic Protein in (DR2 × Ob1)F1 Mice by Induction of IL-10-Secreting iTregs | SpringerLink
Apitope's Phase II multiple sclerosis trial a success
Apitope regains global rights to its multiple sclerosis treatment from Merck
Effects of ATX-MS-1467 immunotherapy over 16 weeks in relapsing multiple sclerosis
Current and emerging disease‐modulatory therapies and treatment targets for multiple sclerosis - Piehl - 2021 - Journal of Internal Medicine - Wiley Online Library
Spatial reference learning deficits in absence of dysfunctional working memory in the TgF344‐AD rat model of Alzheimer's disease - Tournier - 2021 - Genes, Brain and Behavior - Wiley Online Library
Frontiers | Antigen-Specific Treatment Modalities in MS: The Past, the Present, and the Future
ATX-MS-1467 for RRMS
Efficacy results in study 1 | Download Scientific Diagram
B Cell Targeted Therapy in Multiple Sclerosis – New Possibilities - touchNEUROLOGY
ATX-MS-1467 Induces Long-Term Tolerance to Myelin Basic Protein in (DR2 × Ob1)F1 Mice by Induction of IL-10-Secreting iTregs | SpringerLink
Неврология. Эпилепсия: диагностика, лечение, стационар - Антиген специфическая иммуномодуляция препаратом ATX-MS-1467 Инновационный антиген специфической иммуномодулятор ATX-MS-1467 для лечения рассеянного склероза. Основной целью патогенетической ...
머크 KGaA, '아피토프'에 다발성 경화증 치료제 반환 - 바이오스펙테이터
Effects of ATX-MS-1467 immunotherapy over 16 weeks in relapsing multiple sclerosis
2013: School of Cellular and Molecular Medicine | News and features | University of Bristol
